Prof. Dr. med. Fabian Müller

Department of Medicine 5 – Haematology and Oncology Professur für CAR-T-Zell-Therapie

Effects of different B-cell-depleting strategies on the lymphatic tissue (2025) Tur C, Eckstein M, Bucci L, Auth J, Bergmann C, Rauber S, Hagen M, et al. Journal article Comparison of the safety profiles of CD19-targeting CAR T-cell therapy in patients with SLE and B-cell lymphoma (2025) Müller F, Schwingen NR, Hagen M, Scholz JK, Aigner M, Wirsching A, Taubmann J, et al. Journal article CAR-T-Zellen bei nicht-malignen Erkrankungen (2025) Müller F, Hagen M, Schett G, Mackensen A Journal article Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study (2025) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Düsing C, Krickau T, et al. Journal article Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or refractory multiple myeloma: An international multicenter study (2025) Merz M, Albici AM, von Tresckow B, Rathje K, Fenk R, Holderried T, Müller F, et al. Journal article Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy (2024) Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried TA, Fenk R, et al. Journal article Treatment of CNS systemic lupus erythematosus with CD19 CAR T cells (2024) Hagen M, Müller F, Wirsching A, Kharboutli S, Spörl S, Aigner M, Völkl S, et al. Journal article CD19-CAR T-cell therapy induces deep tissue depletion of B cells (2024) Tur C, Eckstein M, Velden J, Rauber S, Bergmann C, Auth J, Bucci L, et al. Journal article Selective CAR T cell–mediated B cell depletion suppresses IFN signature in SLE (2024) Wilhelm A, Chambers D, Müller F, Bozec A, Grieshaber Bouyer R, Winkler T, Mougiakakos D, et al. Journal article CAR T-Cell Therapy in Autoimmune Disease. Reply. (2024) Müller F, Mackensen A, Schett G Journal article, Letter